VSV-hIFNbeta-NIS

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

What's the purpose of the trial?

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter [NIS]) with or without cyclophosphamide or ipilimumab and nivolumab or cemiplimab in treating patients with multiple myeloma, acute myeloid leukemia (AML) or lymphoma that has come back or does not respond to treatment. 

Trial status

Accepting patients

Phase
Phase 1
Enrollment
65
Last Updated
2 months ago
Am I Eligible

Participating Centers

There are 3 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Cemiplimab (REGN2810) is a monoclonal antibody that attaches to the PD-1 protein on the body's immune cells. Cemiplimab may work by stopping cancer cells from being able to inhibit the body's immune system.
  • Ipilimumab is a monoclonal antibody that is approved to treat melanoma, and several other cancers in combination with other therapies.
  • Ruxolitinib is a tyrosine kinase inhibitor in development for the treatment of several different blood cancers.
  • VSV-hIFNbeta-NIS IV is a virus that has been altered in a laboratory and is being evaluated to see if it may be able to kill cancer cells without damaging normal cells.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.